Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation

Table 2 Univariate analysis of the effects of clinicopathological factors on the disease-free survival of patients with hepatocellular carcinoma who underwent liver transplantation

Variable	χ2	P value	HR	95%CI
Gender (F/M)	0.001	0.973	0.990	0.558-1.759
Age, yr (≥ 60/< 60)	4.573	0.0321	0.477	0.242-0.940
Child-Pugh class (A/B/C)
A	-	-	-	-
B	0.291	0.590	1.106	0.766-1.598
C	0.287	0.592	0.827	0.412-1.658
AFP, g/L ( < 400/≥ 400)	6.673	0.0101	1.600	1.120-2.287
NLR (< 4/≥ 4)	24.251	< 0.0011	2.424	1.704-3.440
Preoperative adjuvant therapy (Y/N)	0.019	0.890	1.025	0.721-1.457
Tumor No. ( ≤ 3/> 3)	23.518	< 0.0011	2.524	1.736-3.670
Largest tumor size, cm
≤ 5	-	-	-	-
5-9	11.105	0.0011	2.195	1.382-3.487
> 9	36.829	< 0.0011	3.894	2.510-6.041
Total tumor size, cm
≤ 5	-	-	-	-
5-9	6.590	0.010	2.123	1.195-3.771
> 9	45.107	< 0.0011	5.553	3.358-9.115
Macro-vascular invasion (Y/N)	33.195	< 0.0011	2.904	2.021-4.174
Micro-vascular invasion (Y/N)	31.135	< 0.0011	2.910	1.999-4.234
Differentiation (1-2/3-4)	3.136	0.077	1.435	0.962-2.140
HBV infection (Y/N)	0.012	0.912	1.048	0.461-2.382
Donor (living/deceased)	0.480	0.488	1.163	0.759-1.780

¹Significant P value. NLR: Neutrophil-lymphocyte ratios; AFP: α-fetoprotein; HBV: Hepatitis B virus.